PEA |
Palmitoylethanolamide |
eCB |
Endocannabinoid |
NAE |
N-acyl-ethanolamine |
PPARα |
Peroxisome proliferator-activated receptor-α |
GPR55 |
G protein-coupled receptor 55 |
GPR119 |
G protein-coupled receptor 119 |
CB1 |
Cannabinoid receptor 1 |
CB2 |
Cannabinoid receptor 1 |
AEA |
Anandamide |
TRPV1 |
Transient receptor potential vanilloid 1 |
MC |
Mast cells |
ALIA |
Autacoid Local Inflammation Antagonism |
TNF-α
|
Tumour necrosis factor αlpha
|
IL |
Interleukin |
ICAM-1 |
Intercellular Adhesion Molecule 1
|
NF-κB |
Nuclear factor kappa B |
CNS |
Central nervous system |
FAAH |
Fatty acid amide hydrolase |
GALT |
Gut-associated lymphoid tissue |
GIT |
Gastrointestinal tract |
CAD |
Contact allergic dermatitis |
AD |
Alzheimer’s disease |
PD |
Parkinson’s Disease |
TBI |
Traumatic brain injury |
ASD |
Autism spectrum disorder |
Bcl-2 |
B-cell lymphoma 2 |
BAX |
Bcl-2-associated X protein |
Akt |
Protein kinase B |
mTOR |
Mechanistic target of rapamycin |
P70S6k |
Ribosomal protein S6 kinase beta-1 |
PTSD |
Post-traumatic stress disorder |
CDR |
Cell Danger Response |
BDNF |
Brain-derived neurotrophic factor |
GDNF |
Glial cell line-derived neurotrophic factor |
GBA |
Gut–brain axis |
LPS |
Lipopolysaccharides |
BBB |
Blood–brain barrier |
TTH |
Tension-type headaches |
NSAIDs |
Non-steroidal anti-inflammatory drugs |
PGF2α |
Prostaglandin F2-α
|
PGE2
|
Prostaglandin E2
|
OA |
Osteoarthritis |
TMJ |
Temporomandibular joint |
WOMAC |
Western Ontario and McMaster Universities Osteoarthritis Index |
EIMD |
Exercise-induced muscle damage |
DOMS |
Delayed onset muscle soreness |
CBD |
Cannabidiol |
CTS |
Carpal tunnel syndrome |